Business, energy, technology, markets and global industry news from Business News Today

QUILT-3.032

PharmaDeviceNews QUILT-3.032
ImmunityBio’s ANKTIVA has received United Arab Emirates marketing authorization for BCG-unresponsive bladder cancer and previously treated metastatic non-small cell lung cancer, expanding the immunotherapy’s international regulatory footprint. Representative image.
Pharma & Biotech

Why ImmunityBio’s UAE authorization gives ANKTIVA a broader cancer label than it has in the United States

ImmunityBio gains UAE authorization for ANKTIVA in broader bladder cancer and metastatic lung cancer uses, widening its Gulf commercial opportunity.

Read More
Representative image of an oncology researcher reviewing bladder cancer treatment data, as ImmunityBio’s ANKTIVA plus BCG analysis raises new questions about cost, response durability and bladder-sparing care in BCG-unresponsive NMIBC.
Pharma & Biotech

Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate

Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.

Read More
Pharma & Biotech

Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise

ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.

Read More
Pharma & Biotech

Macau clears ImmunityBio’s ANKTIVA for BCG-unresponsive NMIBC, opening Asia market amid commercialization test

ImmunityBio's first Asia approval for ANKTIVA in BCG-unresponsive bladder cancer: what the Macau clearance means for its global strategy. Read the analysis.

Read More